Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.

NCT Number	NCT06094101
Lead Sponsor	University Hospital Tuebingen Collaborators: Deutsches Konsortium fürTranslationale Krebsforschung (DKTK), Cooperative Ewing Sarkom Studiengruppe, Cooperative Weichteilsarkom Study Group
Conditions	Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
Enrollment	30 participants
Start Date	2023-09-19
Primary Completion	2027-06 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-04